Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.07
+0.54003.99%
Post-market: 14.05-0.0200-0.14%19:47 EDT
Volume:1.35M
Turnover:18.88M
Market Cap:570.71M
PE:-2.81
High:14.20
Open:13.42
Low:13.42
Close:13.53
Loading ...

Stock Track | Keros Therapeutics Soars 6.89% Following Analyst Upgrades and Buy Ratings

Stock Track
·
13 Dec 2024

Scotiabank Keeps Their Buy Rating on Keros Therapeutics (KROS)

TIPRANKS
·
13 Dec 2024

Truist Financial Issues a Buy Rating on Keros Therapeutics (KROS)

TIPRANKS
·
13 Dec 2024

Keros Therapeutics Inc : Scotiabank Cuts Target Price to $44 From $77

THOMSON REUTERS
·
13 Dec 2024

Keros Therapeutics Inc : Jefferies Cuts Target Price to $23 From $113

THOMSON REUTERS
·
13 Dec 2024

Keros Therapeutics Inc : Leerink Partners Cuts Target Price to $35 From $85

THOMSON REUTERS
·
13 Dec 2024

Keros Therapeutics Cut to Market Perform From Outperform by William Blair

Dow Jones
·
13 Dec 2024

Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher

Benzinga
·
13 Dec 2024

BofA cuts Keros target to $33, says ‘story still intact’ despite ‘setback’

TIPRANKS
·
13 Dec 2024

Keros Therapeutics Prospects Still Strong Despite Cibotercept Hurdles, Wedbush Says

MT Newswires Live
·
13 Dec 2024

Keros Therapeutics Cut to Hold From Buy by TD Cowen

Dow Jones
·
13 Dec 2024

Wedbush Adjusts Price Target on Keros Therapeutics to $47 From $84, Keeps Outperform Rating

MT Newswires Live
·
12 Dec 2024

Keros Therapeutics Inc : Wedbush Cuts Target Price to $47 From $84

THOMSON REUTERS
·
12 Dec 2024

Keros Therapeutics Inc : TD Cowen Cuts to Hold From Buy

THOMSON REUTERS
·
12 Dec 2024

BUZZ-Keros Therapeutics hits all-time low as safety concerns halt trial dosing

Reuters
·
12 Dec 2024

TD Cowen downgrades Keros Therapeutics (KROS) to a Hold

TIPRANKS
·
12 Dec 2024

Keros Therapeutics Shares Fall 76.3% After Halting Dosing in Trial of Experimental Drug for Rare Type of Blood Disorder, Btig Cuts to Neutral

THOMSON REUTERS
·
12 Dec 2024

Keros Therapeutics Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
12 Dec 2024

Keros Therapeutics (KROS) was downgraded to a Hold Rating at BTIG

TIPRANKS
·
12 Dec 2024

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires Live
·
12 Dec 2024